Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Zucara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Zucara Therapeutics"},{"company":"HEC Group","sponsor":"Lannett","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Peptide","productStatus":"Biosimilar","date":"February 2021","url1":"","url2":"","graph1":"Peptide","graph2":"HEC Group"}]

HEC Group

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin

Details:

The biosimilar insulin aspart is currently in development and Lannett will help manage the remaining clinical and regulatory steps specific for a U.S. Food and Drug Administration (FDA) approval to market the product.

Lead Product(s): Insulin aspart

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Peptide

Partner/Sponsor/Collaborator: Lannett

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration February 09, 2021

ASK
US

Upload
your Pipeline Activity

Zucara Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes

Details:

The expansion of our ZT-01 development program is based on promising results in a preclinical model of T2D and represents the potential to benefit a substantially larger population.

Lead Product(s): ZT-01

Therapeutic Area: Endocrinology Product Name: ZT-01

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 02, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY